📊 2026-11-22
• Cancer Breakthroughs: FDA Approves Durvalumab Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancer and Pimicotinib for TGCT in Week of New Oncology Approvals
• mRNA Revolution: BioNTech mRNA Cancer Vaccine Fails Phase 3 Trial, Rattling Oncology Confidence
🔗 watchboard.dev
📊 2026-11-22 • Cancer Breakthroughs: FDA Approves Durvalumab Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancer and Pimicotinib for TGCT in Week of New Oncology Approvals • mRNA Revolution: BioNTech mRNA Cancer Vaccine Fails Phase 3 Trial, Rattling Oncology Confidence 🔗 watchboard.dev
0 vue
Publié le 22/11/2026 05:11
0:23
📊 2026-11-22
• Cancer Breakthroughs: FDA Approves Durvalumab Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancer and Pimicotinib for TGCT in Week of New Oncology Approvals
• mRNA Revolution: BioNTech mRNA Cancer Vaccine Fails Phase 3 Trial, Rattling Oncology Confidence
🔗 watchboard.dev
0 commentaire
?